IRIS
BALLABENI, Vigilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.125
EU - Europa 5.597
AS - Asia 2.940
SA - Sud America 189
AF - Africa 99
Continente sconosciuto - Info sul continente non disponibili 24
OC - Oceania 3
Totale 14.977
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.968
CN - Cina 1.668
FI - Finlandia 1.209
SE - Svezia 1.037
SG - Singapore 944
IE - Irlanda 938
UA - Ucraina 688
IT - Italia 586
DE - Germania 563
TR - Turchia 215
GB - Regno Unito 170
BR - Brasile 164
CA - Canada 134
RU - Federazione Russa 85
BE - Belgio 66
CI - Costa d'Avorio 57
FR - Francia 57
AT - Austria 52
RO - Romania 46
IN - India 36
CZ - Repubblica Ceca 29
CM - Camerun 25
EU - Europa 24
NL - Olanda 21
BD - Bangladesh 13
ES - Italia 11
PA - Panama 11
IQ - Iraq 8
MX - Messico 8
AZ - Azerbaigian 7
MA - Marocco 7
EC - Ecuador 6
ID - Indonesia 6
PK - Pakistan 6
VN - Vietnam 6
EE - Estonia 5
HK - Hong Kong 5
IR - Iran 5
KR - Corea 5
LT - Lituania 5
AR - Argentina 4
CL - Cile 4
CO - Colombia 4
DK - Danimarca 4
SC - Seychelles 4
SI - Slovenia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
PH - Filippine 3
PL - Polonia 3
PT - Portogallo 3
AU - Australia 2
BG - Bulgaria 2
DO - Repubblica Dominicana 2
HR - Croazia 2
HU - Ungheria 2
MD - Moldavia 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TN - Tunisia 2
AL - Albania 1
AM - Armenia 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CR - Costa Rica 1
DZ - Algeria 1
EG - Egitto 1
GY - Guiana 1
IM - Isola di Man 1
JM - Giamaica 1
JP - Giappone 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PY - Paraguay 1
RS - Serbia 1
SN - Senegal 1
TW - Taiwan 1
UY - Uruguay 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 14.977
Salva come PNG Salva come JPEG
Città #
Dublin 937
Chandler 911
Jacksonville 743
Singapore 573
Santa Clara 558
Dearborn 450
Ann Arbor 448
Beijing 339
Ashburn 299
Boardman 288
Nanjing 242
Izmir 194
Parma 181
Princeton 179
Shanghai 160
New York 148
San Mateo 132
Wilmington 127
Toronto 102
Helsinki 101
Bremen 88
Hebei 83
Kunming 78
Jinan 75
Nanchang 75
Shenyang 75
Moscow 66
Grafing 64
Brussels 63
Hefei 58
Abidjan 57
Woodbridge 54
Los Angeles 51
Vienna 48
Des Moines 43
Guangzhou 43
Changsha 42
Tianjin 42
Chicago 30
Seattle 29
Fremont 27
Jiaxing 27
Auburn Hills 24
Munich 23
Norwalk 23
Bologna 21
London 21
Hangzhou 20
Marseille 20
Pune 20
West Jordan 19
Brno 17
Frankfurt am Main 17
Council Bluffs 16
Dallas 16
Zhengzhou 16
Milan 15
Taiyuan 15
Ottawa 14
Haikou 12
Timisoara 12
Fuzhou 11
Houston 11
Kocaeli 11
Lanzhou 11
Mestre 11
Nuremberg 11
São Paulo 11
Taizhou 11
Düsseldorf 10
Carpi 9
Falkenstein 9
Lubbock 9
Montréal 9
Ningbo 9
Chengdu 8
Mordano 8
Amsterdam 7
Baku 7
Madrid 7
Modena 7
Palermo 7
Jakarta 6
Montegaldella 6
Prague 6
Redwood City 6
Rio de Janeiro 6
Xian 6
Bari 5
Belo Horizonte 5
Borås 5
Brescia 5
Campinas 5
Chongqing 5
Edinburgh 5
Faenza 5
Focsani 5
Jinhua 5
Naples 5
Prata Di Pordenone 5
Totale 8.961
Salva come PNG Salva come JPEG
Nome #
1,5-Benzodiazepines Part XIII. Substututed 4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-amines and 4H-imidazo-[1,2-a][ 1,5]benzodiazepin-5-amines as analgesic, anti-inflammatory and/or antipyretic agents with low acute toxicity 265
1,5-Benzodiazepin tricyclic derivatives as analgersic, anti-inflammatory and /or antipyretic agents with very low acute gastrolesivity and toxicity 209
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 209
1,8-Naphthyridines V. Novel N-substituted 5-amino-N,N-diethyl-9-isopropyl [1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamides, as potent anti-inflammatory and/or analgesic agents completely devoid of acute gastrolesivity 161
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 142
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 136
Antiplatelet and antithrombotic activities of essential oil from wild Ocotea quixos (Lam.) Kosterm. (Lauraceae) calices from Amazonian Ecuador 134
2-Aminobenzimidazoles as new potent H3-antagonists 127
Protective Effects of a Protease Inhibitor (Gabexate Mesilate) on Intestinal Ischemia/Reperfusion Injury in Rats 126
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 124
Antinociceptive and gastroprotective effects of inhaled and orally administered Lavandula hybrida Reverchon “Grosso” essential oil 123
Caratterizzazione farmacologica in vitro di nuovi agonisti muscarinici analoghi dell'Oxotremorina 121
Analgesic properties of benzisothiazole/ benzimidazole derivatives with acidic groups 117
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 116
1,8-Naphthyridines VIII. Novel 5-aminoimidazo[1,2-a] [1,8]naphthyridine-6-carboxamide and 5-amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6-carboxamide derivatives showing potent analgesic or anti-inflammatory activity, respectively, and completely devoid of acute gastrolesivity. 113
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 112
2,4-Substituted benzopyrano[4,3-d]pyrimidines and benzopyrano[4,3-d]pyrimidin-5-ones: synthesis and antiplatelet activity 109
Adaptive changes in rat ileum motility induced by mild mesenteric ischemia/reperfusion injury: role of endogenous mediators and reperfusion time 109
Suppression of inflammatory events associated to intestinal ischemia-reperfusion by 5-HT1A blockade in mice 109
Nuovi potenti agonisti muscarinici oxotremorina-M simili a struttura acetilenica: studio funzionale in vitro 109
The Role of HB-Donor Groups in the Heterocyclic Polar Fragment of H3-Antagonists. I. Synthesis and Biological Assays 108
Accommodation and peristalsis are functional responses to chronic obstruction in rat hypertrophic ileum 106
1,8-Naphthyridines VII. New substituted 5-amino[1,2,4]triazolo[4,3-a][1,8]naphthyridine-6-carboxamides and their isosteric analogues, exhibiting notable anti-inflammatory and/or analgesic activities, but no acute gastrolesivity. 106
QSAR study of 2-aminobenzimidazole derivatives as H3 antagonists 105
2-Amino-1,2-benzisothiazolin-3-one derivatives as powerful antiplatelet agents 104
Histamine H4 receptor antagonism and mesenteric ischemia/reperfusion injury in mice 103
Access to CNS of selected H3-antagonists: ex vivo binding study in rats 103
Gastrointestinal symptoms and local oxidative stress in a model of Parkinson's Disease in rats 103
Daily assumption of fermented milk containing Bifidobacterium breve 246 B® promotes prophylactic effects against intestinal inflammation in mice 101
Enteric dysfunctions in experimental Parkinson's disease: alterations of excitatory cholinergic neurotransmission regulating colonic motility in rats 101
Aminobenzimidazoles as new potent H3-antagonists 101
Validation of a histamine H3 receptor model through structure–activity relationships for classical H3 antagonists 100
Regional differences in motor responsiveness to antimuscarinic drugs in rabbit isolated small and large intestine 100
Cognition enhancing effect in rats of a selected histamine H3 receptor antagonist with good brain penetration 99
Analgesici-antipiretici benzopirano pirimidinici non acidici attivi per via orale privi di gastrolesività 99
R-a-methylhistamine-induced inhibition of gastric acid secretion in pylorus-ligated rats via central histamine H3 receptors 99
Influence of adenosine in the systemic and local injury caused by mesenteric ischemia-reperfusion in mice 98
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 98
A New Potent and Selective Histamine H3-Receptor Antagonist, 4(5)-{2-[4(5)-cyclohexylimidazol-2-ylthio]ethyl}imidazole 96
Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis 95
Mesenteric ischemia-reperfusion: an overview of preclinical drug strategies 94
Motor responses of rat hypertrophic intestine following chronic obstruction 94
Synthesis and biological assays of new H3-antagonists with imidazole and imidazoline polar groups 93
Intestinal chronic obstruction affects motor responsiveness of rat hypertrophic longitudinal and circular muscles 92
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 92
Assessment of intestinal motor responsiveness in an ischemia/reperfusion model in rats 91
A promising imidazole-free histamine H3 receptor antagonist with good brain penetration and anticholinesterase activity. 91
Novel antiplatelet and antithrombotic activities of essential oil from Lavandula hybrida Reverchon "Grosso" 90
Different role of the Histamine H3 Receptor in Vagal-, Betanechol-, Pentagastrin-induced Gastric Acid Secretion in Anaesthetized Rats 90
Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity 90
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 89
Accommodation and peristalsis are functional responses to obstruction in rat hypertrophic ileum 89
Synthesis and pharmacological screening of novel non-acidic gastric-sparing antiinflammatory/antiplatelet agents:5-alkyl/cycloalkylamino substituted 2-amino-5H-[1]benzopyrano[4,3-d]pyrimidines 88
Plasma concentration and brain penetration of the H3-receptor antagonist Thioperamide in rats 87
Role of 5-HT in intestinal ischemia-reperfusion: suppression of inflammatory events by 5-HT1A blockade in mice 87
Influence of Nitric Oxide system in mesenteric ischemia-reperfusion induced injury in mice 87
CNS access of selected H3-antagonists: ex vivo binding study in rats 86
Interactions of new and conventional H3-blockers with non-histaminergic receptors involved in neurogenic and myogenic contractile responses of guinea-pig ileum 86
Farmaci Lassativi e Farmaci Antidiarroici 86
Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: Comparative study with conventional in vivo techniques in the rat 86
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 85
Dibasic non-imidazole histamine H3 receptor antagonists with a rigid byphenyl scaffold. 85
In vitro and in vivo pharmacological analysis of imidazole-free histamine H3 receptor antagonists: promising results for a brain-penetrating H3 blocker with weak anticholinesterase activity. 85
Role of Glutamate- N-methyl-D-Aspartate (NMDA) Receptors in Neuronal Plasticity and Gastrointestinal Transit Delay Induced by Ischemia/Reperfusion in Rats 85
Radiological analysis of gastrointestinal dysmotility associated with central dopaminergic impairment in an animal model of parkinson's disease (PD) 84
Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation. 84
Discovery of small-molecule targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases 83
5-Alkoxy-2-hydrazino and 5-methoxy-2-amino-5H[1]benzopyrano[4,3-d]pyrimidines: synthesis and pharmacological activity 83
Synthesis and functional characterization of novel heterocyclic derivatives related to oxotremorine and oxotremorine-M 83
Functional Studies of New Imidazole H3-Antagonists on Guinea-Pig Isolated Preparations 83
5-HT1A receptors as target to protect the intestine in an experimental model of colitis 83
Disruption of Eph-ephrin B signaling pathways mitigates inflammation in a murine model of Crohn’s disease 83
Synthesis, biological activity, QSAR and QSPR study of 2/aminobenzimidazole derivatives as potent H3-antagonists 83
Access to CNS of selected H3-antagonists: ex vivo binding study in rats 83
Protection by the EPH-EPHRIN System Against Mesenteric Ischemia-Reperfusion Injury 83
New analogues of oxotremorine and oxotremorine-M: estimation of their in vitro affinity and efficacy at muscarinic receptor subtypes 82
Assessment of intestinal motor responsiveness in an ischemia/reperfusion model in rats 82
Preliminary study of calcium balance and bone mineralization improvement by a new calcium supplement in growing rats 82
Anomalous responses to histamine stimulation of guinea-pig oesophageal muscularis mucosae. 81
Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity. 81
Dual-Acting Drugs: an in vitro Study of Nonimidazole Histamine H(3) Receptor Antagonists Combining Anticholinesterase Activity 80
Anomalous responses to histamine stimulation of guinea-pig oesophageal muscularis mucosae 80
Development and validation of a LC-MS method with electrospray ionization for the determination of the imidazole H(3) antagonist ROS203 in rat plasma. 79
Functional study of the central access of chemical delivery systems developed as g-aminobutyric acid (GABA) prodrugs 78
Comparative screening of plant essential oils: phenylpropanoid moiety as basic core for antiplatelet activity 78
Alterations of intestinal motor responsiveness in a model of mild mesenteric ischemia/reperfusion in rats 78
2-Amino-1,2-benzisothiazolin-3-one Derivatives: Synthesis and Assessment of their Antiplatelet/Spasmolytic Effects 78
Preventive effect of 5-HT1A receptor agonist Buspirone on mesenteric ischemia/reperfusion-induced inflammatory injuries in mice 78
Functional comparison between nuvenzepine and pirenzepine on different guinea pig isolated smooth muscle preparations 77
New potent acethylenic muscarinic agonists related to oxotremorine-M: in vitro functional study 77
Discovery of histamine H3 receptor antagonistic property of simple imidazole-free derivatives: preliminary pharmacological investigation. 77
Synthesis and pharmacological evaluation of 2,5-cycloamino-5H-[1]benzopyrano-[4,3-di]pyrimidines endowed with in vitro antiplatelet activity 76
Sviluppo e caratterizzazione farmacologica di un nuovo potente e selettivo H3-bloccante istaminico non-tioureico 76
Screening di nuovi agenti antiinfiammatori/antiaggreganti non-acidici: sviluppo di 2-amino-5H-[1]benzopirano[4,3-d]pirimidine 5-alchil/cicloalchilamino sostituite prive di attivita' gastrolesiva 76
Histamine H3-antagonists: the basicity of the polar group in quantitative structure-activity and structure-property relationship 76
Inhibitors of blood platelet aggregation: synthesis and in vitro characterization of 2-amino-1,2-benzisothiazolin-3-one derivatives 75
Investigation on the anti-inflammatory properties of Ocotea quixos Lam. essential oil. 75
Novel triazolonaphthyridine derivatives: potent and highly effective agents in the control of inflammation and pain in rodents 74
Relationship between structure and ex-vivo binding of imidazole H3 antagonists to rat brain H3 receptors 74
Proteinase-Activated Receptor 2 agonist prevents mesenteric ischemia/reperfusion injury in rats: partila involvement of Substance P (SP) and Calcitonin-Gene Related Peptide (CGRP) 74
Totale 9.783
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.066
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.066
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020701 0 0 0 0 0 0 0 0 280 171 81 169
2020/20211.388 25 170 157 21 174 52 183 19 292 47 211 37
2021/20221.034 24 30 25 111 62 85 121 136 41 65 77 257
2022/20233.734 445 375 229 259 385 411 71 213 1.124 40 121 61
2023/20241.332 81 106 45 52 106 348 115 67 49 74 95 194
2024/20252.497 122 227 295 225 367 499 144 182 436 0 0 0
Totale 15.112